<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>65</patient-age><report-id>JP-NOVOPROD-369154</report-id><gender>female</gender><reactions><reaction>Tumour enlargement</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>Norditropin FlexPro 10 mg/ml</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>DECADRON                           /00016001/</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>THYRADIN S</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Growth hormone deficiency</indication><indication>Blood corticotrophin abnormal</indication><indication>Blood thyroid stimulating hormone decreased</indication></indications><patient-age>65</patient-age><outcomes/><country>Japan</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>170157_050</messagenumb>
		<messagesenderidentifier>NOVOPROD</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151547</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>JP-NOVOPROD-369154</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>2</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2013-01-15</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-16</receiptdate>
		<additionaldocument>1</additionaldocument>
		<documentlist>E2b Differences Report</documentlist>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>JP-NOVOPROD-369154</companynumb>
		<primarysource>
			<reportercountry>JP</reportercountry>
			<qualification code="1">Physician</qualification>
			<studyname>#Trial Title:A multicentre, open label, observational, non-interventional study to evaluate on long-</studyname>
			<sponsorstudynumb>GH-3811</sponsorstudynumb>
			<observestudytype>3</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVOPROD</senderorganization>
			<senderdepartment>Product Safety and Clinical Quality Assurance</senderdepartment>
			<sendergivename>Novo</sendergivename>
			<sendermiddlename>Nordisk</sendermiddlename>
			<senderfamilyname>Inc.</senderfamilyname>
			<senderstreetaddress>100 College Road West</senderstreetaddress>
			<sendercity>Princeton</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>08540</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>6099875831</sendertel>
			<sendertelcountrycode>1</sendertelcountrycode>
			<senderfax>6099878480</senderfax>
			<senderfaxcountrycode>1</senderfaxcountrycode>
			<senderemailaddress>NNPI_AE_REPORTING@NOVONORDISK.COM</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDAEDI.CDER</receiverdepartment>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3018276504</receivertel>
			<receivertelcountrycode>1</receivertelcountrycode>
			<receiveremailaddress>WTaylor@OC.FDA.GOV</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientonsetage>65</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientagegroup>5</patientagegroup>
			<patientweight>52.6</patientweight>
			<patientheight>145</patientheight>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Growth hormone deficiency</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Craniopharyngioma</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>1995</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Tumour enlargement</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Tumour enlargement</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Neoplasm</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120613</reactionstartdate>
				<reactionfirsttime>512</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>Norditropin FlexPro 10 mg/ml</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationnumb>21-148</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Novo Nordisk A/S</drugauthorizationholder>
				<drugstructuredosagenumb>.3</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>0.3 mg, qd</drugdosagetext>
				<drugdosageform normalized="solution for injection">Solution for injection</drugdosageform>
				<drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Growth hormone deficiency</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-01-18</drugstartdate>
				<drugstartperiod>512</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>SOMATROPIN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Neoplasm</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Unlikely</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Neoplasm</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>DECADRON                           /00016001/</medicinalproduct>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Blood corticotrophin abnormal</drugindication>
				<activesubstance>
					<activesubstancename>DEXAMETHASONE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>THYRADIN S</medicinalproduct>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Blood thyroid stimulating hormone decreased</drugindication>
				<activesubstance>
					<activesubstancename>LEVOTHYROXINE SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Study ID: <Semaphore x="2807886" class="MedDRA LLT" value="Blood growth hormone" score="1.00" ID="10005571">GH </Semaphore>3811Study description: A multicentre, open label, observational, non interventional study to evaluate on long term safety and efficacy of <Semaphore x="931905" class="Medicine" value="Norditropin" score="0.87" ID="241346">Norditropin </Semaphore>formulation in patients with AGHD (Limited to Severe Conditions).Phase: ObservationalPatient ID: <Semaphore x="2664954" class="Occupation" value="Unlicensed Assistive Personnel" score="1.00" ID="C20861">UNKNOWN</Semaphore>Centre ID: <Semaphore x="2664954" class="Occupation" value="Unlicensed Assistive Personnel" score="1.00" ID="C20861">UNKNOWN</Semaphore>Patient's <Semaphore x="1387854" class="Height" value="145 cm" score="1.00" ID="">height: <Semaphore x="5960787541622785" class="Height" value="145 cm" score="1.00" ID="">145 cm</Semaphore></Semaphore>.This serious solicited case from Japan was <Semaphore x="2210075" class="Procedure" value="Medical Research Council Dyspnea Scale" score="1.00" ID="C21157">reported by medical </Semaphore><Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">doctor </Semaphore>as "<Semaphore x="3133749" class="MedDRA LLT" value="Neoplasm progression" score="1.00" ID="10061309"><Semaphore x="2266803" class="Disease or Finding" value="Neoplasm by Cause" score="1.00" ID="C27933">tumor </Semaphore>enlargement</Semaphore>". It <Semaphore x="1805433" class="Procedure" value="Concern About Finances" score="1.00" ID="C104604">concerns </Semaphore>a 65-year old female patient treated with <Semaphore x="931905" class="Medicine" value="Norditropin" score="0.87" ID="241346">Norditropin </Semaphore>FlexPro 10 mg/ml (<Semaphore x="1209757" class="Medicine" value="Somatropin" score="0.49" ID="276826">somatropin</Semaphore>) from 18-Jan 2011 and ongoing due to <Semaphore x="1995963" class="Disease or Finding" value="Growth Hormone Deficiency" score="1.00" ID="C112835">growth <Semaphore x="2032177" class="Disease or Finding" value="Hormone-Resistant Breast Cancer" score="1.00" ID="C114932">hormone </Semaphore>deficiency</Semaphore>.Medical history includes <Semaphore x="1995963" class="Disease or Finding" value="Growth Hormone Deficiency" score="1.00" ID="C112835">growth <Semaphore x="2032177" class="Disease or Finding" value="Hormone-Resistant Breast Cancer" score="1.00" ID="C114932">hormone </Semaphore>deficiency </Semaphore>and <Semaphore x="1821312" class="Disease or Finding" value="Craniopharyngioma" score="1.00" ID="C2964">craniopharyngioma</Semaphore>.The patient developed "<Semaphore x="3133749" class="MedDRA LLT" value="Neoplasm progression" score="1.00" ID="10061309"><Semaphore x="2266803" class="Disease or Finding" value="Neoplasm by Cause" score="1.00" ID="C27933">tumour </Semaphore>enlargement</Semaphore>" on 13-JUN 2012. The patient reportedly received an <Semaphore x="2044649" class="Procedure" value="Imaging Technique" score="1.00" ID="C17369">imaging </Semaphore>test (unspecified), which revealed that a small <Semaphore x="2311429" class="AnatomicStructure" value="Node" score="1.00" ID="C45804">node </Semaphore>on <Semaphore x="2647102" class="AnatomicStructure" value="Tuberculum Sellae" score="1.00" ID="C45911">tuberculum sellae </Semaphore>had been <Semaphore x="1888569" class="Procedure" value="Enlargement Of Surgical Incision" score="1.00" ID="C50835">enlarged</Semaphore>.Action taken to <Semaphore x="931905" class="Medicine" value="Norditropin" score="0.87" ID="241346">Norditropin </Semaphore>FlexPro was reported as no change.The overall <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the events was reported as not yet recovered.Reporter's causality: possibleNovo Nordisk's causality: unlikelyThis case was upgarded to serious ("medically significant") on 16-JAN 2013 by Novo Nordisk.Comment: company comment: <Semaphore x="2070992" class="Disease or Finding" value="Intracranial Neoplasm" score="1.00" ID="C4953">Intracranial <Semaphore x="3133987" class="MedDRA LLT" value="Neoplasm" score="1.00" ID="10028980">neoplasms </Semaphore></Semaphore>often recur after a period of clinical <Semaphore x="2458238" class="Disease or Finding" value="Remission" score="1.00" ID="C18246">remission</Semaphore>. <Semaphore x="1884852" class="Procedure" value="Endocrine Therapy" score="1.00" ID="C15445">Treatment with <Semaphore x="2539990" class="Procedure" value="Somatotrophin Measurement" score="1.00" ID="C80360">growth <Semaphore x="2032177" class="Disease or Finding" value="Hormone-Resistant Breast Cancer" score="1.00" ID="C114932">hormone </Semaphore></Semaphore></Semaphore>has not been shown to increase the risk of <Semaphore x="2453473" class="Disease or Finding" value="Recurrent Malignant Neoplasm" score="1.00" ID="C4813">recurrence </Semaphore>(1, 2).1. Jostel A, Mukherjee A, Hulse <Semaphore x="2398421" class="Occupation" value="Physician Assistant" score="1.00" ID="C53423">PA</Semaphore>, Shalet SM. <Semaphore x="2102861" class="Occupation" value="Legal Occupations" score="1.00" ID="C97637">Adult </Semaphore><Semaphore x="2807886" class="MedDRA LLT" value="Blood growth hormone" score="1.00" ID="10005571"><Semaphore x="2539990" class="Procedure" value="Somatotrophin Measurement" score="1.00" ID="C80360">growth <Semaphore x="2032177" class="Disease or Finding" value="Hormone-Resistant Breast Cancer" score="1.00" ID="C114932">hormone </Semaphore></Semaphore>
     <Semaphore x="3012077" class="MedDRA LLT" value="Hormone therapy" score="1.00" ID="10065646">
      <Semaphore x="3012036" class="MedDRA LLT" value="Hormone replacement therapy" score="1.00" ID="10020388">
       <Semaphore x="2032125" class="Procedure" value="Hormone Replacement Therapy" score="1.00" ID="C15599">
        </Semaphore></Semaphore></Semaphore></Semaphore>
    <Semaphore x="3012077" class="MedDRA LLT" value="Hormone therapy" score="1.00" ID="10065646">
     <Semaphore x="3012036" class="MedDRA LLT" value="Hormone replacement therapy" score="1.00" ID="10020388">
      <Semaphore x="2032125" class="Procedure" value="Hormone Replacement Therapy" score="1.00" ID="C15599">
       <Semaphore x="1884852" class="Procedure" value="Endocrine Therapy" score="1.00" ID="C15445">replacement therapy </Semaphore></Semaphore></Semaphore></Semaphore>and neuroimaging surveillance in <Semaphore x="1627243" class="Disease or Finding" value="Brain Neoplasm" score="1.00" ID="C2907">brain tumour </Semaphore>survivors. Clin Endocrinol. 2005;62:698-705.2. Chung <Semaphore x="1872615" class="Race" value="Eastern Cherokee" score="1.00" ID="C44942">TT</Semaphore>, Drake WM, Evanson J, Walker D, Plowman PN, Chew SL, Grossman AB, Besser <Semaphore x="1975291" class="Disease or Finding" value="Germinal Centers with Prominent Hyalinized Vessels Present" score="1.00" ID="C41006">GM</Semaphore>, Monson JP. <Semaphore x="2266803" class="Disease or Finding" value="Neoplasm by Cause" score="1.00" ID="C27933">Tumour </Semaphore>surveillance <Semaphore x="2044649" class="Procedure" value="Imaging Technique" score="1.00" ID="C17369">imaging </Semaphore>in patients with extrapituitary <Semaphore x="2266803" class="Disease or Finding" value="Neoplasm by Cause" score="1.00" ID="C27933">tumours </Semaphore>receiving <Semaphore x="2539990" class="Procedure" value="Somatotrophin Measurement" score="1.00" ID="C80360">growth <Semaphore x="2032177" class="Disease or Finding" value="Hormone-Resistant Breast Cancer" score="1.00" ID="C114932">hormone </Semaphore></Semaphore>replacement. Clin Endocrinol. 2005;63:274-9.</narrativeincludeclinical>
				<sendercomment>Intracranial neoplasms often recur after a period of clinical remission. Treatment with growth hormone has not been shown to increase the risk of recurrence (1, 2). 

1. Jostel A, Mukherjee A, Hulse PA, Shalet SM. Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clin Endocrinol. 2005;62:698-705.  

2. Chung TT, Drake WM, Evanson J, Walker D, Plowman PN, Chew SL, Grossman AB, Besser GM, Monson JP. Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement. Clin Endocrinol. 2005;63:274-9.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>